AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro

AstraZeneca's (AZN) Lynparza is now "king" of its realm in cancer treatments — beating out rival Tesaro (TSRO) — an analyst said Friday after the U.K.-based drugmaker reported sales of the cancer drug that crushed expectations.

X During the fourth quarter, AstraZeneca reported $54 million in U.S. sales of Lynparza, smashing the consensus view for $39 million, RBC analyst Kennen MacKay said in a note to clients. That beat Tesaro's guidance for $40 million to $50 million in sales of...

What feeling does this article give you?

#hashtags to follow:

AZN [+]    Lynparza [+]    Tesaro [+]    TSRO [+]    RBC [+]    Kennen MacKay [+]   

More #news: